Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uwe Platzbecker

Showing results (1-10 of 482) with videos related to

Pageof 49
Sort By:
Blood|January 24, 2019
Treatment of MDSUwe Platzbecker
Seminars in Hematology|October 20, 2012
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndromesUwe Platzbecker
Hematology. American Society of Hematology. Education Program|December 10, 2013
Who benefits from allogeneic transplantation for myelodysplastic syndromes?: new insightsUwe Platzbecker
Seminars in Hematology|September 30, 2017
Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitorsAnna Mies, Uwe Platzbecker
Blood Advances|November 13, 2019
Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?Felicitas Thol, Uwe Platzbecker
Best Practice & Research. Clinical Haematology|February 11, 2014
Allogeneic stem cell transplantation in MDS: how? When?Uwe Platzbecker, Ghulam Mufti
Drugs|November 24, 2018
Current and Future Treatment Options for Myelodysplastic Syndromes: More Than Hypomethylating Agents and Lenalidomide?Katja Sockel, Uwe Platzbecker
Current Hematologic Malignancy Reports|October 5, 2013
When to transplant MDS, and what to do when transplant failsKatja Sockel, Uwe Platzbecker
Hematology/Oncology Clinics of North America|December 3, 2014
Transplants in myelodysplastic syndromesKatrin Wetzko, Uwe Platzbecker
International Journal of Molecular Sciences|August 10, 2019
Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic SyndromesAnne Sophie Kubasch, Uwe Platzbecker
Pageof 49

Showing results (1-10 of 482) with videos related to

Sort By:
Pageof 49
Blood|January 24, 2019
Treatment of MDSUwe Platzbecker
Seminars in Hematology|October 20, 2012
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndromesUwe Platzbecker
Hematology. American Society of Hematology. Education Program|December 10, 2013
Who benefits from allogeneic transplantation for myelodysplastic syndromes?: new insightsUwe Platzbecker
Seminars in Hematology|September 30, 2017
Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitorsAnna Mies, Uwe Platzbecker
Blood Advances|November 13, 2019
Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?Felicitas Thol, Uwe Platzbecker
Best Practice & Research. Clinical Haematology|February 11, 2014
Allogeneic stem cell transplantation in MDS: how? When?Uwe Platzbecker, Ghulam Mufti
Drugs|November 24, 2018
Current and Future Treatment Options for Myelodysplastic Syndromes: More Than Hypomethylating Agents and Lenalidomide?Katja Sockel, Uwe Platzbecker
Current Hematologic Malignancy Reports|October 5, 2013
When to transplant MDS, and what to do when transplant failsKatja Sockel, Uwe Platzbecker
Hematology/Oncology Clinics of North America|December 3, 2014
Transplants in myelodysplastic syndromesKatrin Wetzko, Uwe Platzbecker
International Journal of Molecular Sciences|August 10, 2019
Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic SyndromesAnne Sophie Kubasch, Uwe Platzbecker
Pageof 49